Sunshine Heart Appoints Warren Watson to Board of Directors

Sunshine Heart Appoints Warren Watson to Board of Directors 
Seasoned Leader in Cardiology Joins as Director Replacing William
EDEN PRAIRIE, MN and SYDNEY, AUSTRALIA -- (Marketwire) -- 01/30/13 --
 Sunshine Heart, Inc. (NASDAQ: SSH) (ASX: SHC) today announced that
Warren Watson has been appointed to the Company's Board of Directors.
Mr. Watson replaces William Peters, MD, who steps down from the Board
but continues on as Chief Technical Officer of Sunshine Heart. Both
changes are effective immediately.  
Mr. Watson brings over 35 years of experience in medical devices to
Sunshine Heart, including 33 years at Medtronic, Inc., where he
served in various roles of increasing responsibility spanning
technical management, clinical and regulatory processes, business
development, strategic marketing, and general management. Notably, he
spent eight years as VP of Research and Development for the Cardiac
Rhythm Management business. In addition to corporate officer roles,
Mr. Watson has served on the Board of Directors of several U.S.
cardiology companies. He was a member of the Board of
California-based cardiology company, Cameron Health, which was bought
by Boston Scientific in 2012. He currently serves on the Board of
Cardialen, Inc. and Cardia Access, both Minneapolis-based early stage
medical device companies.  
"We are thrilled to welcome Warren to our Board," said John Erb,
Chairman of Sunshine Heart's Board of Directors. "Warren's
exceptional tenure at Medtronic will be a significant asset to our
company. His experience guiding medical technology companies comes at
a key time for Sunshine Heart, as we continue to progress our
proprietary C-Pulse Heart Assist System through the U.S. regulatory
process into pivotal trials, and initiate European post-market
studies toward a European commercial launch." 
"Will Peters has been nothing short of instrumental to the growth and
success of Sunshine Heart since co-founding the company in 1999,"
said Dave Rosa, CEO of Sunshine Heart. "We thank him for his service
on our Board and look forward to his continued contributions as a
corporate officer." 
The addition of a new U.S. Board member furthers Sunshine Heart's
corporate transition to becoming a U.S.-centric company. In tandem
with this release, Sunshine Heart announced yesterday its intention
to de-list from the ASX during the first half of calendar 2013. This
follows its February, 2012 listing on NASDAQ.  
About Sunshine(R) Heart  
Sunshine Heart, Inc. (NASDAQ: SSH) (ASX: SHC) is an early-stage
global medical device company committed to the commercialization of
the C-Pulse System, an implantable, non-blood contacting, heart
assist therapy for the treatment of moderate to severe heart failure.
The C-Pulse System can be implanted using a minimally invasive
procedure and is designed to relieve the symptoms of heart failure
through the use of counter-pulsation technology, which enables an
increase in cardiac output, an increase in coronary blood flow and a
reduction in the heart's pumping load. Sunshine Heart has completed
an approved U.S. Food and Drug Administration (FDA) feasibility
clinical trial of the C-Pulse System and presented the results in
November 2011. In March, 2012, the FDA notified the Company that it
could move forward with an investigational device exemption (IDE)
application. Sunshine Heart received unconditional approval from the
FDA in November 2012 to initiate its pivotal trial. In July 2012,
Sunshine Heart received CE Mark approval for its C-Pulse System in
Europe. Sunshine Heart is a Delaware corporation headquartered in
Minneapolis with a subsidiary presence in Australia. The Company has
been listed on the Australian Securities Exchange (ASX) since
September 2004 and on the NASDAQ Capital Market since February 2012.
For more information, please visit 
Forward-Looking Statements  
Certain statements in this release are forward-looking statements
that are based on management's beliefs, assumptions and expectations
and information currently available to management. All statements
that address future operating performance, events or developments
that we expect or anticipate will occur in the future are
forward-looking statements, including without limitation, our
expectations with respect to future clinical trial activities and
results including patient enrollment in trials. These forward-looking
statements are subject to numerous risks and uncertainties, including
without limitation, the possibility that our clinical trials do not
meet their enrollment goals, meet their end-points or otherwise fail,
that regulatory authorities do not accept our application or approve
the marketing of the C-Pulse System, the possibility we may be unable
to raise the funds necessary for the development and
commercialization of our products, that we may not be able to
commercialize our products successfully in the EU and the other risk
factors described under the caption "Risk Factors" and elsewhere in
our filings with the U.S. Securities and Exchange Commission and ASX.
You should not place undue reliance on forward-looking statements
because they speak only as of the date when made and may turn out to
be inaccurate. We do not assume any obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise. We may not actually achieve
the plans, projections or expectations disclosed in forward-looking
statements, and actual results, developments or events could differ
materially from those disclosed in the forward-looking statements. 
For further information, please contact:  
Laura Forman 
Blueprint Life Science Group 
T: +1-415-375-3340  
Jeff Mathiesen
Chief Financial Officer
Sunshine Heart, Inc. 
T: +1-952-345-4200 
Press spacebar to pause and continue. Press esc to stop.